FrancophonIA/ELRC3.0 huggingface dataset:
English: The median time to first onset in lenvatinib-treated patients was 10.1 weeks.
Danish: Den mediane tid til første symptom hos lenvatinibbehandlede patienter var 10,1 uger.
English: LENVIMA 4 mg hard capsules LENVIMA 10 mg hard capsules lenvatinib
Danish: LENVIMA 4 mg hårde kapsler LENVIMA 10 mg hårde kapsler lenvatinib
English: Electrolyte disturbances such as hypokalaemia, hypocalcaemia, or hypomagnesaemia increase the risk of QT prolongation; therefore, electrolyte abnormalities should be monitored and corrected in all patients before starting treatment.
Danish: Elektrolytforstyrrelser, såsom hypokaliæmi, hypocalcæmi eller hypomagnesæmi, øger risikoen for QT-forlængelse.
English: LENVIMA 4 mg hard capsules
Danish: LENVIMA 4 mg hårde kapsler
English: Patients with end-stage renal disease were not studied, therefore the use of lenvatinib in these patients is not recommended.
Danish: Derfor anbefales anvendelse af lenvatinib ikke til disse patienter.
English: LENVIMA 10 mg hard capsules
Danish: Lenvima 10 mg hårde kapsler
English: In the pivotal Phase 3 SELECT trial (see section 5.1), 88% of all patients had a baseline TSH level less than or equal to 0.5 mU/L.
Danish: 5.1) havde 88 % af alle patienter et niveau af TSH ved baseline, der var under eller lig med 0,5 mE/l.
English: Hepatic encephalopathy (including fatal events in 4 patients) occurred in 8.4% of patients (5.5% were ≥ Grade 3).
Danish: Leversvigt (herunder letale hændelser hos 12 patienter) forekom hos 3,6% af patinterne (alle var ≥ grad 3) Hepatisk encefalopati (inklusive letale hændelser hos 4 patienter) forekom hos 8,4 % af patienterne (5,5 % var ≥ grad 3).
English: QT/QTc interval prolongation has been reported at a higher incidence in patients treated with lenvatinib than in patients treated with placebo (see section 4.8, Description of selected adverse reactions).
Danish: Forlængelse af QT/QTc-intervallet er blevet rapporteret med en større forekomst hos patienter i behandling med lenvatinib end hos patienter i placebobehandling (se pkt.
English: In the pivotal Phase 3 SELECT trial (see section 5.1), proteinuria was reported in 33.7% of lenvatinibtreated patients and 3.1% of patients in the placebo-treated group.
Danish: 5.1) blev proteinuri rapporteret hos 33,7 % af de lenvatinibbehandlede patienter og hos 3,1% af patienterne i gruppen, der fik placebo.
English: There were 17 (3.6%) deaths due to hepatotoxicity events in the lenvatinib arm and 4 (0.8%) deaths in the sorafenib arm. Hepatotoxicity adverse reactions led to dose interruptions and reductions in 12.2% and 7.4% of lenvatinib-treated patients respectively, and to permanent discontinuation in 5.5%.
Danish: Der var 17 (3,6 %) dødsfald på grund af hændelser med hepatotoksicitet i lenvatinib-armen og 4 (0,8 %) dødsfald i sorafenib-armen.
English: In the Phase 3 REFLECT trial (see section 5.1), haemorrhage was reported in 24.6% of patients and 5.0% were Grade ≥ 3.
Danish: 5.1) blev blødning rapporteret hos 24,6 % af patienterne, og 5,0 % var grad ≥ 3.
English: In the pivotal Phase 3 SELECT trial (see section 5.1), arterial thromboembolic events were reported in 5.4% of lenvatinib-treated patients and 2.3% of patients in the placebo group.
Danish: 5.1) blev arterielle tromboemboliske hændelser rapporteret hos 5,4 % af de lenvatinibbehandlede patienter og hos 2,3 % af patienterne i gruppen, der fik placebo.
English: Thyroid cancer
Danish: Skjoldbruskkirtelkræft
English: • The recommended dose of LENVIMA is usually 24 mg once a day
Danish: • Den anbefalede dosis af LENVIMA er normalt 24 mg én gang dagligt (2 kapsler med 10 mg og
English: Quartiles are estimated by the Kaplan-Meier method, and the 95% CIs are estimated with a generalized Brookmeyer and Crowley method f.
Danish: e Kvartiler er estimeret med Kaplan-Meier-methoden, og 95 % CI er estimeret med en generaliseret Brookmeyer og Crowley-method f Responsrate (fuldstændigt eller delvist respons) g Uafhængig radiologisk gennemgang ved retrospektiv analyse.
English: In the pivotal Phase 3 SELECT trial (see section 5.1), events of gastrointestinal perforation or fistula were reported in 1.9% of lenvatinib-treated patients and 0.8% of patients in the placebo group.
Danish: 5.1) blev hændelser med mave-tarm-perforation eller fistel rapporteret hos 1,9 % af de lenvatinibbehandlede patienter og hos 0,8 % af patienterne i gruppen, der fik placebo.
English: • inflammation of the gallbladder
Danish: • betændelse i galdeblæren
English: Dose interruptions, adjustments, or discontinuation may be necessary (see section 4.2).
Danish: Dosisafbrydelser, -justeringer eller -seponering kan være nødvendig (se pkt.
English: • If you have severe liver or kidney problems the recommended dose is 14 mg once a day
Danish: • Hvis du har svære problemer med lever eller nyrer, er den anbefalede dosis 14 mg én gang dagligt (1 kapsel med 10 mg og 1 kapsel med 4 mg).
English: NAME OF THE MEDICINAL PRODUCT LENVIMA 4 mg hard capsules lenvatinib STATEMENT OF ACTIVE SUBSTANCE(S) Each hard capsule contains 4 mg lenvatinib (as mesilate).
Danish: LÆGEMIDLETS NAVN LENVIMA 4 mg hårde kapsler lenvatinib ANGIVELSE AF AKTIVT STOF/AKTIVE STOFFER Hver hård kapsel indeholder 4 mg lenvatinib (som mesilat).
English: NAME OF THE MEDICINAL PRODUCT LENVIMA 4 mg hard capsules LENVIMA 10 mg hard capsules
Danish: LÆGEMIDLETS NAVN LENVIMA 4 mg hårde kapsler LENVIMA 10 mg hårde kapsler
English: The majority of cases recovered or resolved following dose interruption or reduction, which occurred in 13.0% and 13.4% of patients, respectively.
Danish: De fleste tilfælde blev bedre eller gik væk efter dosisafbrydelse eller -reduktion, hvilket forekom hos hhv. 13,0 % og 13,4 % af patienterne.
English: In the Phase 3 REFLECT trial (see section 5.1), 7.1% of lenvatinib-treated patients developed a renal failure/impairment event.
Danish: 5.1) udviklede 7,1 % af lenvatinib-patienter et nyresvigt/en hændelse med svækkelse.
English: Blood Pressure (BP) level
Danish: Blodtryksniveau
English: Optimal medical management (i.e. treatment or therapy) for nausea, vomiting, and diarrhoea should be initiated prior to any lenvatinib therapy interruption or dose reduction; gastrointestinal toxicity should be actively treated in order to reduce the risk of development of renal impairment or failure (see section 4.4, Renal failure and impairment).
Danish: Optimal medicinsk behandling (dvs. behandling eller terapi) af kvalme, opkastning og diarré bør påbegyndes før en afbrydelse eller dosisreduktion af lenvatinib.
English: OR
Danish: Eller
English: Or
Danish: ELLER
English: In the lenvatinib arm, median OS was 19.5 months (95% CI: 15.7, 23.0) for subjects who received post-treatment anticancer therapy (43%) and 10.5 months (95% CI: 8.6, 12.2) for those who did not.
Danish: I begge behandlingsarme i REFLECT-atudiet var median OS ca. 9 måneder længere for forsøgspersoner, der fik post-behandling med anti-cancer-terapi i forhold til dem, der ikke fik det. I lenvatinib-armen var median OS 19,5 % (95 % CI: 15,7; 23,0) for forsøgspersoner, der fik postbehandling med anti-cancerterapi (43%) og 10,5 måneder (95 % CI: 8,6; 12,2) for dem, der ikke gjorde det. I sorafenib-armen var median OS 17,0 måneder (95 % CI: 14,2, 18,8) for forsøgspersoner, der fik post-behandling fik med anti-cancerterapi (51%) og 7,9 måneder (95 % CI: 6,6; 9,7) for dem, der ikke gjorde det.
English: Impaired healing*
Danish: Nedsat heling*
English: Gastrointestinal perforation or fistulae have been reported in patients treated with lenvatinib (see section 4.8).
Danish: Mave-tarm-perforation eller fistel er blevet rapporteret hos patienter i behandling med lenvatinib (se pkt.
English: Diarrhoea has been reported frequently in patients treated with lenvatinib, usually occurring early in the course of treatment (see section 4.8, Description of selected adverse reactions).
Danish: Diarré er blevet rapporteret hyppigt hos patienter i behandling med lenvatinib, sædvanligvis tidligt i behandlingsforløbet (se pkt.
English: 8 mg (two 4 mg capsules) orally once daily
Danish: 8 mg (to 4 mg kapsler) oralt en gang dagligt
English: In the Phase 3 REFLECT trial (see section 5.1), events of gastrointestinal perforation or fistula were reported in 1.9% of lenvatinib-treated patients.
Danish: 5.1) blev hændelser med mave-tarm-perforation eller fistel rapporteret hos 1,9 % af de lenvatinib-behandlede patienter.
English: Management of adverse reactions may require dose interruption, adjustment, or discontinuation of lenvatinib therapy (see section 4.4).
Danish: Behandling af bivirkninger kan kræve dosisafbrydelse, justering eller seponering af lenvatinibbehandlingen (se pkt.
English: Description of selected adverse reactions
Danish: Beskrivelse af udvalgte bivirkninger DTC
English: Action
Danish: Virkning
English: How to take LENVIMA
Danish: Sådan skal du tage LENVIMA
English: Lenvatinib impairs exogenous thyroid suppression (see section 4.8, Description of selected adverse reactions).
Danish: Lenvatinib hæmmer eksogen tyreoideaundertrykkelse (se pkt.
English: Fatigue Asthenia Peripheral oedema
Danish: Træthed Asteni Perifert ødem
English: Haemorrhage terms that occurred in 5 or more subjects with DTC were: epistaxis, haemoptysis, haematuria, contusion, haematochezia, gingival bleeding, petechial, pulmonary haemorrhage, rectal haemorrhage, blood urine present, haematoma and vaginal haemorrhage.
Danish: Termer for blødning, der forekom hos 5 eller flere patienter med DTC var: epistaxis, hæmoptyse, hæmaturi, kontusion, hæmatokesi, blødning fra tandkød, petekkier, lungeblødning, rektal blødning, blod i urinen, hæmatom og vaginalblødning.
English: It may harm them,
Danish: Tid (måneder)
English: Hypocalcaemia (see section 4.4, QT interval prolongation)
Danish: 4.4 Forlængelse af QT-intervallet)
English: Hypertension and proteinuria tend to occur early during lenvatinib treatment (see sections 4.4 and 4.8, Description of selected adverse reactions).
Danish: Hypertension og proteinuri havde en tendens til at forekomme tidligt i behandlingen med lenvatinib (se pkt.
English: Leukopenia includes leukopenia and decreased white blood cell count Lymphopenia includes lymphopenia and lymphocyte count decreased.
Danish: Lymfopeni omfatter lymfopeni og et nedsat antal lymfocytter.
English: LENVIMA 4 mg hard capsules: - Each hard capsule contains 4 mg of lenvatinib (as mesylate).
Danish: LENVIMA 4 mg hårde kapsler: Hver hård kapsel indeholder 4 mg lenvatinib (som mesilat).
English: Haemorrhage
Danish: Miltinfarkt
English: In the case of hepatotoxicity, dose interruptions, adjustments, or discontinuation may be necessary (see section 4.2).
Danish: I tilfælde af hepatotoksicitet kan det være nødvendigt med dosisafbrydelser, dosisjusteringer eller seponering (se pkt.
English: • The 10 mg capsule is a yellow body and yellowish red cap, approximately 14.3 mm in length, marked in black ink with “Є” on the cap, and “LENV 10 mg” on the body.
Danish: • Kapslen med 10 mg er en gul underdel og en gullig rød hætte, ca. 14,3 mm lang, præget med sort blæk med ”Є” på hætten, og med ”LENV 10 mg” på underdelen.
English: In the Phase 3 REFLECT trial (see section 5.1), arterial thromboembolic events were reported in 2.3% of patients treated with lenvatinib.
Danish: 5.1) blev arterielle tromboemboliske hændelser rapporteret hos 2,3 % af patienterne, der blev behandlet med lenvatinib.
English: Hepatotoxicity (see section 4.4)
Danish: Hepatotoksicitet (se pkt.
English: 4 mg (one 4 mg capsule) orally once daily
Danish: 4 mg (en 4 mg kapsel) oralt en gang dagligt
English: NAME OF THE MEDICINAL PRODUCT LENVIMA 10 mg hard capsules lenvatinib STATEMENT OF ACTIVE SUBSTANCE(S) Each hard capsule contains 10 mg lenvatinib (as mesilate).
Danish: LÆGEMIDLETS NAVN LENVIMA10 mg hårde kapsler lenvatinib ANGIVELSE AF AKTIVT STOF/AKTIVE STOFFER Hver hård kapsel indeholder 10 mg lenvatinib (som mesilat).
English: • The 4 mg capsule is a yellowish red body and yellowish red cap, approximately 14.3 mm in length, marked in black ink with “Є” on the cap, and “LENV 4 mg” on the body.
Danish: • Kapslen med 4 mg er en gullig, rød underdel og en gullig rød hætte, ca. 14,3 mm lang, præget med sort blæk med ”Є” på hætten, og med ”LENV 4 mg” på underdelen.
English: Possible side effects
Danish: Effektparameter
English: The median time to objective responsive was 2.0 (95% CI: 1.9, 3.5) months; however, of the patients who experienced a complete or partial response to lenvatinib, 70.4% were observed to develop the response on or within 30 days of being on the 24-mg dose.
Danish: Ud af de patienter, der oplevede et fuldstændigt eller delvist respons på lenvatinib, blev det imidlertid observeret, at 70,4 % udviklede et respons ved eller inden for 30 dage, efter de påbegyndte dosen på 24 mg.
English: LENVIMA 10 mg hard capsules Each hard capsule contains 10 mg of lenvatinib (as mesylate).
Danish: LENVIMA 10 mg hårde kapsler Hver hård kapsel indeholder 10 mg lenvatinib (som mesilat).
English: LENVIMA 10 mg hard capsules: - Each hard capsule contains 10 mg of lenvatinib (as mesylate).
Danish: LENVIMA 10 mg hårde kapsler: Hver hård kapsel indeholder 10 mg lenvatinib (som mesilat).
English: In the case of a gastrointestinal perforation or fistula, dose interruptions, adjustments, or discontinuation may be necessary (see section 4.2).
Danish: I tilfælde af mave-tarm-perforation eller fistel kan det være nødvendigt med dosisafbrydelser, -justeringer eller seponering (se pkt.
English: • liver damage
Danish: • problemer med sårheling
English: Wound Healing Complications
Danish: Komplikationer ved sårheling
English: Renal impairment or failure
Danish: Nedsat nyrefunktion eller nyresvigt
English: 4 mg (one 4 mg capsule) orally every other day
Danish: 4 mg (en 4 mg kapsel) oralt hver andendag
English: A single 32-mg dose of lenvatinib did not prolong the QT/QTc interval based on results from a thorough QT study in healthy volunteers; however, QT/QTc interval prolongation has been reported at a higher incidence in patients treated with lenvatinib than in patients treated with placebo (see sections 4.4 and 4.8).
Danish: En enkelt dosis på 32 mg lenvatinib forlængede ikke QT/QTc-intervallet, baseret på resultater fra et grundigt QT-studie af raske frivillige.
English: Other special populations
Danish: 4.2) Andre specielle populationer
English: Renal failure and impairment (see section 4.4)
Danish: Nyresvigt og nedsat nyrefunktion (se pkt.
English: Increased blood thyroid stimulating hormone (see section 4.4 Impairment of thyroid stimulating hormone suppression / Thyroid dysfunction)
Danish: 4.4 Hæmning af tyreoideastimulerende hormonsuppression/tyreoideadysfunktion)
English: A yellow body and yellowish-red cap, approximately 14.3 mm in length, marked in black ink with “Є” on the cap, and “LENV 10 mg” on the body.
Danish: En gul underdel og en gullig-rød hætte, ca. 14,3 mm lang, præget med sort blæk med ”Є” på hætten, og med ”LENV 10 mg” på underdelen.
English: Hypertension has been reported in patients treated with lenvatinib, usually occurring early in the course of treatment (see section 4.8, Description of selected adverse reactions).
Danish: Der er blevet rapporteret om hypertension hos patienter i behandling med lenvatinib, der sædvanligvis opstod tidligt i behandlingsforløbet (se pkt.
English: Proteinuria has been reported in patients treated with lenvatinib, usually occurring early in the course of treatment (see section 4.8, Description of selected adverse reactions).
Danish: Der er blevet rapporteret om proteinuri hos patienter i behandling med lenvatinib, hvilket sædvanligvis opstod tidligt i behandlingsforløbet (se pkt.
English: Hypothyroidism has been reported in patients treated with lenvatinib (see section 4.8, Description of selected adverse reactions).
Danish: Der er blevet rapporteret hypotyreoidisme hos patienter i behandling med lenvatinib (se pkt.
English: In the case of bleeding, dose interruptions, adjustments, or discontinuation may be required (see Section 4.2, Table 3).
Danish: I tilfælde af blødning kan det være nødvendigt med dosisafbrydelser, -justeringer eller -seponering (se pkt.
English: A yellowish-red body and yellowish-red cap, approximately 14.3 mm in length, marked in black ink with “Є” on the cap, and “LENV 4 mg” on the body.
Danish: En gullig-rød underdel og en gullig-rød hætte, ca. 14,3 mm lang, præget med sort blæk med ”Є” på hætten, og med ”LENV 4 mg” på underdelen.
English: Hepatic failure and acute hepatitis (<1%; see section 4.8, Description of selected adverse reactions) have been reported in patients with DTC treated with lenvatinib.
Danish: 4.8 Beskrivelse af udvalgte bivirkninger) hos patienter med DTC i behandling med lenvatinib.
English: Malaise
Danish: Hypotyroidisme
English: LENVIMA
Danish: Seponering
English: • feeling unwell
Danish: • følelse af svimmelhed
English: Name and address of the manufacturer responsible for batch release Eisai Manufacturing Ltd
Danish: Navn og adresse på den fremstiller, der er ansvarlig for batchfrigivelse
English: Cardiac dysfunction (see section 4.4)
Danish: Hjertedysfunktion (se pkt.
English: Constipation Dyspepsia Dry mouth
Danish: Obstipation Dyspepsi Mundtørhed
English: What LENVIMA is and what it is used for What you need to know before you take LENVIMA How to take LENVIMA
Danish: Det skal du vide, før du begynder at tage LENVIMA Sådan skal du tage LENVIMA Bivirkninger
English: Haemorrhage terms that occurred in 5 or more subjects with HCC were: epistaxis, haematuria, gingival bleeding, haemoptysis, oesophageal varices haemorrhage, haemorrhoidal haemorrhage, mouth haemorrhage, rectal haemorrhage and upper gastrointestinal haemorrhage.
Danish: Termer for blødning, der forekom hos 5 eller flere patienter med HCC var: epistaxis, hæmaturi, blødning fra tandkød, hæmoptyse, blødende esophagusvaricer, blødende hæmorroider, blødning i munden, rektal blødning og øvre mave-tarm-blødning.
English: Renal impairment and renal failure have been reported in patients treated with lenvatinib (see section 4.8, Description of selected adverse reactions).
Danish: Nedsat nyrefunktion og nyresvigt er blevet rapporteret hos patienter i behandling med lenvatinib (se pkt.
English: • stroke
Danish: • udslæt
English: Impaired wound healing has been reported in patients receiving lenvatinib.
Danish: Der er rapporteret om nedsat sårheling hos patienter, som fik lenvatinib.
English: Posology
Danish: Seponer
English: Non-Gastrointestinal fistulae (see section 4.4)
Danish: og perkutan ethanol injektion (4 %)
English: Withhold lenvatinib
Danish: Afbryd lenvatinib
English: What LENVIMA looks like and contents of the pack
Danish: Udseende og pakningsstørrelser
English: It is available as pink, round tablets (75 mg).
Danish: Det fås som lyserøde runde tabletter (75 mg).
English: The standard dose of Clopidogrel Mylan is one 75 mg tablet once a day, taken with or without food.
Danish: Standarddosis af Clopidogrel Mylan er én 75 mg -tablet én gang dagligt med eller uden et måltid.
English: The European Commission granted a marketing authorisation valid throughout the EU for Clopidogrel Mylan to Mylan S.A.S on 21 September 2009.
Danish: Europa-Kommissionen udstedte en markedsføringstilladelse med gyldighed i hele Den Europæiske Union for Clopidogrel Mylan til Mylan S.A.S den 21. september 2009.
English: The full EPAR for the reference medicine can also be found on the Agency's website.
Danish: Den fuldstændige EPAR for referencelægemidlet findes også på EMEA's websted.
English: • patients who have recently had a myocardial infarction (heart attack).
Danish: • patienter, som for nyligt har haft et myokardieinfarkt (hjertetilfælde).
English: This stops the platelets becoming ‘sticky', reducing the risk of a blood clot forming and helping to prevent another heart attack or stroke.
Danish: Dette forhindrer blodpladerne i at blive ”klæbrige” og mindsker således risikoen for, at der dannes blodpropper, og hjælper dermed med at forhindre et hjerte- eller et slagtilfælde.
English: Clopidogrel Mylan can be given to the following groups of patients:
Danish: Clopidogrel Mylan kan gives til følgende patientgrupper:
English: This means that Clopidogrel Mylan is similar to a ‘reference medicine' already authorised in the European Union (EU) called Plavix.
Danish: Det betyder, at Clopidogrel Mylan er identisk med et ‘referencelægemiddel', der allerede er godkendt i Den Europæiske Union (EU), og som hedder Plavix.
English: Clopidogrel Mylan clopidogrel EPAR summary for the public
Danish: Clopidogrel Mylan clopidogrel EPAR - sammendrag for offentligheden
English: Clopidogrel Mylan is used in adults to prevent atherothrombotic events (problems caused by blood clots and hardening of the arteries).
Danish: Clopidogrel Mylan anvendes hos voksne til forebyggelse af aterotrombotiske hændelser hos voksne (problemer forårsaget af blodpropper og åreforkalkning).
English: The Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Clopidogrel Mylan has been shown to have comparable quality and to be bioequivalent to Plavix.
Danish: Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at det i overensstemmelse med EU's krav er blevet påvist, at Clopidogrel Mylan er af sammenlignelig kvalitet og er bioækvivalent med Plavix.
English: The full EPAR for Clopidogrel Mylan can be found here.
Danish: Den fuldstændige EPAR for Clopidogrel Mylan findes her.
English: Other information about Clopidogrel Mylan:
Danish: Andre oplysninger om Clopidogrel Mylan:
English: The Committee recommended that Clopidogrel Mylan be given marketing authorisation.
Danish: Udvalget anbefalede udstedelse af markedsføringstilladelse for Clopidogrel Mylan.
English: Clopidogrel Mylan can be started between a few days and 35 days after the attack;
Danish: Mylan kan påbegyndes få dage efter anfaldet og indtil 35 dage efter
English: What are the benefit and risk of Clopidogrel Mylan?
Danish: Hvilken fordel og risiko er der forbundet med Clopidogrel Mylan?
English: Because Clopidogrel Mylan is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as those of the reference medicine.
Danish: Da Clopidogrel Mylan er et generisk lægemiddel, som er bioækvivalent med referencelægemidlet, anses benefit/risk-forholdet for at være det samme som for referencelægemidlet.
English: Clopidogrel Mylan is a ‘generic medicine'.
Danish: Clopidogrel Mylan er et ‘generisk lægemiddel'.
English: Clopidogrel Mylan can be started between seven days and six months after the stroke;
Danish: Behandling med Clopidogrel Mylan kan påbegyndes 7 dage efter slagtilfældet og indtil 6 måneder efter
English: Because Clopidogrel Mylan is a generic medicine, studies have been limited to tests to determine that it is bioequivalent to the reference medicine, Plavix.
Danish: Da Clopidogrel Mylan er et generisk lægemiddel, har undersøgelserne været begrænset til at påvise, at det er bioækvivalent med referencelægemidlet Plavix.
English: Clopidogrel Mylan is a medicine that contains the active substance clopidogrel.
Danish: Clopidogrel Mylan er et lægemiddel, der indeholder det aktive stof clopidogrel.
English: The active substance in Clopidogrel Mylan, clopidogrel, is an inhibitor of platelet aggregation.
Danish: Det aktive stof i Clopidogrel Mylan, clopidogrel, er en trombocytfunktionshæmmer.
English: Why has Clopidogrel Mylan been approved?
Danish: Hvorfor blev Clopidogrel Mylan godkendt?
English: What is Clopidogrel Mylan?
Danish: Hvad er Clopidogrel Mylan?
English: How has Clopidogrel Mylan been studied?
Danish: Hvordan blev Clopidogrel Mylan undersøgt?
English: What is Clopidogrel Mylan used for?
Danish: Hvad anvendes Clopidogrel Mylan til?
English: How is Clopidogrel Mylan used?
Danish: Hvordan anvendes Clopidogrel Mylan?
English: How does Clopidogrel Mylan work?
Danish: Hvordan virker Clopidogrel Mylan?
English: • improving your ability to perform daily activities.
Danish: • forbedre din evne til at udføre dagligdagsaktiviteter.
English: • The injection can take up to 15 seconds.
Danish: • Injektionen kan tage op til 15 sekunder.
English: 50 to 100
Danish: 50 til 100
English: Date of first authorisation: 23 June 2017
Danish: Dato for første markedsføringstilladelse: 23. juni 2017